The "jack jumper" ant (Myrmecia pilosula) is a major cause of anaphylaxis in Tasmania. We describe four deaths attributed to stings by this ant between 1980 and 1999. All victims were men aged 40 years or over with significant comorbidities; two were taking angiotensin-converting enzyme inhibitors, which may increase risk of severe anaphylaxis. Three victims had known ant-sting allergy, but only one carried adrenaline, which he did not use. Another believed he was protected by previous attempts at hyposensitisation with whole ant-body extract. There is potential to prevent deaths by careful education of people with known allergy, prescribing of adrenaline for auto-injection and development of an effective hyposensitisation therapy.
Correspondence:
- 1.
- Ogata K, Taylor RW. Ants of the genus Myrmecia Fabricus: apreliminary review and key to the named species (Hymenoptera:Formicidae: Myrmeciinae). J Nat Hist 1991; 25: 1623-1673.
- 2.
- Clarke PS. The natural history of sensitivity to jack jumper ants(Hymenoptera formicidae Myrmecia pilosula) in Tasmania.Med J Aust 1986; 145: 564-566.
- 3.
- Douglas R, Weiner J, Abrahamson M, O'Hehir R. Prevalence of severeant venom allergy in southeastern Australia. J Allergy ClinImmunol 1998; 101: 129-131.
- 4.
- Ford SA, Baldo BA, Weiner J, Sutherland S. Identification ofjack-jumper ant (Myrmecia pilosula) venom allergens.Clin Exp Allergy 1991; 21: 167-171.
- 5.
- Donovan GR, Baldo BA, Sutherland S. Molecular cloning andcharacterization of a major allergen (Myr p I) from the venom of theAustralian jumper ant, Myrmecia pilosula. BiochimBiophys Acta 1993; 1171: 272-280.
- 6.
- Donovan GR, Street MD, Tetaz T, et al. Expression of jumper ant(Myrmecia pilosula) venom allergens: post-translationalprocessing of allergen gene products. Biochem Mol Biol Int1996; 39: 877-885.
- 7.
- Street MD, Donovan GR, Baldo BA, Sutherland S. Immediate allergicreactions to Myrmecia ant stings: immunochemical analysisof Myrmecia venoms. Clin Exp Allergy 1994; 24:590-597.
- 8.
- Street MD, Donovan GR, Baldo BA. Molecular cloning andcharacterization of the major allergen Myr p II from the venom of thejumper ant Myrmecia pilosula: Myr p I and Myr p II share a commonprotein leader sequence. Biochim Biophys Acta 1996; 1305:87-97.
- 9.
- Donovan GR, Street MD, Baldo BA. Separation of jumper ant(Myrmecia pilosula) venom allergens: a novel group of highlybasic proteins. Electrophoresis 1995; 16: 804-810.
- 10.
- Australian Bureau of Statistics. 1996 Census of Population andHousing. Basic Community Profiles State of Tasmania (Greater Hobartand Southern Statistical Divisions). Data summaries availableonline [Cited 2001 Nov 04]. Available at<http://www.abs.gov.au/ausstats>
- 11.
- Enander I, Matsson P, Nystrand J, et al. A new radioimmunoassay forhuman mast cell tryptase using monoclonal antibodies. J ImmunolMethods 1991; 138: 39-46.
- 12.
- Fisher MM, Baldo BA. Mast cell tryptase in anaestheticanaphylactoid reactions. Br J Anaesth 1998; 80: 26-29.
- 13.
- Donovan GR, Street MD, Baldo BA, et al. Identification ofan IgE-binding determinant of the major allergen Myr p I from the venomof the Australian jumper ant Myrmecia pilosula. BiochimBiophys Acta 1994; 1204: 48-52.
- 14.
- Tovey ER, Ford SA, Baldo BA. Enhanced immunodetection of blottedhouse dust mite protein allergens on nitrocellulose followingblocking with Tween 20. Electrophoresis 1989; 10: 243-249.
- 15.
- Harvey P, Sperber S, Kette F, et al. Bee-sting mortality inAustralia. Med J Aust 1984; 140: 209-211.
- 16.
- Mosbech H. Death caused by wasp and bee stings in Denmark1960-1980. Allergy 1983; 38: 195-200.
- 17.
- Pumphrey RS, Roberts IS. Postmortem findings after fatalanaphylactic reactions. J Clin Pathol 2000; 53: 273-276.
- 18.
- Pumphrey RS. Lessons for management of anaphylaxis from a study offatal reactions. Clin Exp Allergy 2000; 30: 1144-1150.
- 19.
- Sasvary T, Muller U. Fatalities from insect stings in Switzerland1978 to 1987. Schweiz Med Wochenschr 1994; 124: 1887-1894.
- 20.
- Yunginger JW, Nelson DR, Squillace DL. Laboratory investigationof deaths due to anaphylaxis. J Forensic Sci 1991; 36:857-865.
- 21.
- Ludolph-Hauser D, Rueff F, Fries C, et al. Constitutively raisedserum concentrations of mast-cell tryptase and severe anaphylacticreactions to Hymenoptera stings. Lancet 2001; 357: 361-362.
- 22.
- Edston E, van Hage-Hamsten M. Beta-tryptase measurementspost-mortem in anaphylactic deaths and in controls. Forensic SciInt 1998; 93: 135-142.
- 23.
- Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levelsin patients with acute allergic reactions: An emergencydepartment-based study. J Allergy Clin Immunol 2000; 106 (1Pt 1): 65-71.
- 24.
- Schwartz LB, Yunginger JW, Miller J, et al. Time course ofappearance and disappearance of human mast cell tryptase in thecirculation after anaphylaxis. J Clin Invest 1989; 83:1551-1555.
- 25.
- Roberts-Thomson PJ, Harvey P, Sperber S, et al. Bee stinganaphylaxis in an urban population of South Australia. Asian Pac JAllergy Immunol 1985; 3: 161-164.
- 26.
- Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACEinhibitors and anaphylactoid reactions during venomimmunotherapy. Lancet 1992; 340: 908.
- 27.
- van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, et al.Anaphylactic shock after insect-sting challenge in 138 persons witha previous insect-sting reaction [see comments]. Ann InternMed 1993; 118: 161-168.
- 28.
- Hermann K, von Tschirschnitz M, Ebner von Eschenbacj C, Ring J.Histamine, tryptase, norepinephrine, angiotensinogen,angiotensin-converting enzyme, angiotensin I and II in plasma ofpatients with hymenoptera venom anaphylaxis. Int Arch AllergyImmunol 1994; 104: 379-384.
- 29.
- Saracho R, Martin-Malo A, Martinez I, et al. Evaluation of theLosartan in Hemodialysis (ELHE) Study. Kidney Int 1998; 68Suppl: S125-S129.
- 30.
- Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial ofimmunotherapy in insect hypersensitivity. N Engl J Med 1978;299: 157-161.
- 31.
- Muller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in beesting hypersensitivity. Bee venom versus wholebody extract.Allergy 1979; 34: 369-378.
- 32.
- Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM.Discontinuing venom immunotherapy: Extended observations. JAllergy Clin Immunol 1998; 101: 298-305.
Online responses are no longer available. Please refer to our instructions for authors page for more information.